Rituximab and minimal change nephrotic syndrome: A therapeutic option

Clinical and Experimental Nephrology

Volumn 15, Issue 5, 2011, Pages 641-647

  Takei, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunosuppression; Minimal change nephrotic syndrome; Relapse; Rituximab; Treatment

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; STEROID;

CHILL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LEUKOENCEPHALOPATHY; LUNG FIBROSIS; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; NONHUMAN; PROTEINURIA; RASH; RELAPSE; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROSIS, LIPOID;

EID: 80755153680     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0465-6     Document Type: Review

References (41)

1. JS Cameron 1996 Nephrotic syndrome in the elderly Semin Nephrol 16 319 329 8829270 1:STN:280:DyaK28vislSisA%3D%3D (Pubitemid 26239461)
2. T Takei M Koike K Suzuki S Shirota M Itabashi S Otsubo, et al. 2007 The characteristics of relapse in adult-onset minimal change nephrotic syndrome Clin Exp Nephrol 11 214 217 17891348 10.1007/s10157-007-0484-5 (Pubitemid 47476793)
3. R Cunard CJ Lelly 2002 T cells and minimal change disease J Am Soc Nephrol 13 1409 1411 11961031 10.1097/01.ASN.0000016406.82019.B3 (Pubitemid 34441424)
4. P Grimbert V Audard P Remy P Lang D Sahai 2003 Recent approaches to the pathogenesis of minimal-change nephrotic syndrome Nephrol Dial Transplant 18 245 248 12543875 10.1093/ndt/18.2.245 1:CAS:528:DC%2BD3sXisVClsrw%3D (Pubitemid 36181671)
5. MJ Kemper T Meyer-Jark M Lilova DE Muller-Wiefel 2003 Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome Clin Nephrol 60 242 247 14579938 1:CAS:528:DC%2BD3sXosFalu70%3D (Pubitemid 37258847)
6. T Kanai H Shiraishi T Yamagata T Ito J Odaka T Saito, et al. 2010 Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome Clin Exp Nephrol 14 578 583 20686809 10.1007/s10157-010-0330-z 1:CAS:528: DC%2BC3MXmvVOjtw%3D%3D
7. J Dantal E Bigot W Bogers A Testa F Kriaa Y Jacques, et al. 1994 Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome N Engl J Med 330 7 14 8259160 10.1056/NEJM199401063300102 1:STN:280:DyaK2c%2FotFyqtw%3D%3D (Pubitemid 24018610)
8. MJ Kemper K Zepf I Klaassen A Link DE Muller-Wiefel 2005 Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse Am J Nephrol 25 132 137 15855740 10.1159/000085357 (Pubitemid 40864182)
9. GC Smith 2007 Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol 22 893 898 17310362 10.1007/s00467-006-0427-5 (Pubitemid 46629628)
10. I Avivi S Robinson A Goldstone 2003 Clinical use of rituximab in haematological malignancies Br J Cancer 89 1389 1394 14562003 10.1038/sj.bjc.6601187 1:CAS:528:DC%2BD3sXotFeks7k%3D (Pubitemid 37390853)
11. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese, et al. 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793 2806 16947627 10.1002/art.22025 1:CAS:528:DC%2BD28XhtFWksLjI (Pubitemid 44497758)
12. KG Smith RB Jones SM Burns DR Jayne 2006 Long-term comparison of rituximab for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and pre-treatment Arthritis Rheum 54 2970 2982 16947528 10.1002/art.22046 1:CAS:528:DC%2BD28XhtFWksLnE (Pubitemid 44497778)
13. LM Nadler J Ritz R Hardy JM Pesando SF Schlossman P Stashenko 1981 A unique cell surface antigen identifying lymphoid malignancies of B cell origin J Clin Invest 67 134 140 6969730 10.1172/JCI110005 1:STN:280: DyaL3M%2FpsVChsQ%3D%3D (Pubitemid 11163165)
14. DG Maloney TM Liles DK Czerwinski C Waldichuk J Rosenberg A Grillo-Lopez, et al. 1994 Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 2457 2466 7522629 1:STN:280:DyaK2M%2Fgt12ltg%3D%3D (Pubitemid 24317376)
15. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab, et al. 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 7506951 1:CAS:528:DyaK2cXhtVCnu70%3D (Pubitemid 24030569)
16. DT Selewski GV Shah RJ Mody PA Rajdev SK Mukherji 2010 Rituximab (Rituxan) AJNR Am J Neuroradiol 31 1178 1180 20448016 10.3174/ajnr.A2142
17. MD Pescovitz 2006 Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action Am J Transplant 6 5 Pt1 859 866 16611321 10.1111/j.1600-6143.2006.01288.x 1:CAS:528:DC%2BD28XkvF2gsb8%3D (Pubitemid 44356635)
18. JH Anolik J Barnard A Cappione AE Pugh-Bernard RE Felgar RJ Looney, et al. 2004 Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus Arthritis Rheum 50 3580 3590 15529346 10.1002/art.20592 1:CAS:528:DC%2BD2cXhtVOqtrjK (Pubitemid 39488683)
19. K Kamei S Ito K Nozu S Fujinaga M Nakayama M Sako, et al. 2009 Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children Pediatr Nephrol 24 1321 1328 19421786 10.1007/s00467-009-1191-0
20. K Tobinai Y Kobayashi M Narabayashi M Ogura Y Kagami Y Morishima, et al. 1998 Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group Ann Oncol 9 527 534 9653494 10.1023/A:1008265313133 1:STN:280: DyaK1czhslektA%3D%3D (Pubitemid 28270641)
21. CA Vieira A Agarwal BK Book RA Sidner CM Bearden HM Gebel, et al. 2004 Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1 Safety, pharmacodynamics, and pharmacokinetics Transplantation 77 542 548 15084932 10.1097/01.TP.0000112934.12622.2B 1:CAS:528:DC%2BD2cXis1Kju7s%3D (Pubitemid 38282809)
22. H Genberg A Hansson A Wernerson L Wennberg G Tyden 2006 Pharmacodynamics of rituximab in kidney allotransplantation Am J Transplant 6 2418 2428 16925569 10.1111/j.1600-6143.2006.01497.x 1:CAS:528:DC%2BD28XhtFGqsrbK (Pubitemid 44359429)
23. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D (Pubitemid 28363048)
24. RA Sidner BK Book A Agarwal CM Bearden CA Vieira MD Pescovitz 2004 In vivo human B-cell subset recovery after in vivo depeletion with rituximab, anti-human CD20 monoclonal antibody Hum Antibodies 13 55 62 15598985 1:CAS:528:DC%2BD2cXhtVahsLnI (Pubitemid 40164116)
25. F Fakhouri N Bocquet P Taupin C Presne MF Gagnadoux P Landais, et al. 2003 Steroid-sensitive nephrotic syndrome: from childhood to adulthood Am J Kidney Dis 41 550 557 12612977 10.1053/ajkd.2003.50116 (Pubitemid 36278371)
26. RD Gilbert E Hulse S Rigden 2006 Rituximab therapy for steroid-dependent minimal change nephrotic syndrome Pediatr Nephrol 21 1698 1700 16932900 10.1007/s00467-006-0228-x (Pubitemid 44390835)
27. H Francois E Daugas A Bensman P Ronco 2007 Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations Am J Kidney Dis 49 158 161 17185157 10.1053/j.ajkd.2006.10.015 1:CAS:528:DC%2BD2sXhsFSjsbs%3D (Pubitemid 44932200)
28. JM Hofstra JK Deegens JF Wetzels 2007 Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transplant 22 2100 2102 17389619 10.1093/ndt/gfm128 (Pubitemid 47244800)
29. HP Peters NC van de Kar JF Wetzels 2008 Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature Neth J Med 66 408 415 19011266 1:CAS:528: DC%2BD1cXhsFCiu7fO
30. T Yang CC Nast A Vo SC Jordan 2008 Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy Nephrol Dial Transplant 23 377 380 17981884 10.1093/ndt/gfm592 (Pubitemid 351767391)
31. Y Sawara M Itabashi C Kojima H Tabata D Kamei K Kawanishi, et al. 2009 Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome Clin Nephrol 72 69 72 19640390 1:CAS:528:DC%2BD1MXhtV2jurbJ
32. N Kurosu H Sugiura C Iwasaki Y Asamiya C Kojima T Moriyama, et al. 2009 Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome Intern Med 48 1901 1904 19881243 10.2169/internalmedicine.48.2435
33. V Guigonis A Dallocchio V Baudouin M Dehennault C Hachon-Le Camus M Afanetti, et al. 2008 Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases Pediatr Nephrol 23 1269 1279 18465150 10.1007/s00467-008-0814-1
34. AL Sellier-Leclerc MA Macher C Loirat V Guerin H Watier M Peuchmaur, et al. 2010 Rituximab efficiency in children with steroid-dependent nephrotic syndrome Pediatr Nephrol 25 1109 1115 20238230 10.1007/s00467-010-1465-6
35. A Gulati A Sinha SC Jordan P Hari AK Dinda S Sharma, et al. 2010 Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report Clin J Am Soc Nephrol 5 2207 2212 20798255 10.2215/CJN.03470410 1:CAS:528:DC%2BC3MXpsVKmuw%3D%3D
36. P Quartier B Brethon P Philippet J Landman-Parker F Le Deist A Fischer 2001 Treatment of childhood autoimmune haemolytic anaemia with rituximab Lancet 358 1511 1513 11705566 10.1016/S0140-6736(01)06573-4 1:CAS:528: DC%2BD3MXot1Ojtb4%3D (Pubitemid 33055705)
37. CF Wong 2007 Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol Dial Transplant 22 32 36 17056639 10.1093/ndt/gfl573 1:CAS:528:DC%2BD2sXivFCqtw%3D%3D (Pubitemid 46050323)
38. KR Carson AM Evens EA Richey TM Habermann D Focosi JF Seymour, et al. 2009 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood 113 4834 4840 19264918 10.1182/blood-2008-10- 186999 1:CAS:528:DC%2BD1MXmslalsbw%3D
39. MC Chaumais A Garnier F Chalard M Peuchmaur S Dauger E Jacqz-Agrain G Deschenes 2009 Fata pulmonary fibrosis after rituximab administration Pediatr Nephrol 24 1753 1755 19396468 10.1007/s00467-009-1195-9
40. DS Ardelean T Gonska S Wires E Cutz A Griffiths E Harvey, et al. 2010 Severe ulcerative colitis after rituximab therapy Pediatr Nephrol 126 e243 e246
41. H Sugiura T Takei M Itabashi M Tsukada T Moriyama C Kojima, et al. 2011 Effect of single-dose rituximab on primary glomerular diseases Nephron Clin Pract 117 c98 c105 20693810 10.1159/000319656 1:CAS:528:DC%2BC3MXhtlWjs78%3D